Predict your next investment

HEALTHCARE | Drug Discovery
visterrainc.com

See what CB Insights has to offer

Executives

7

Board of Directors

7

Visterra Board of Directors

7 Board of directors

Visterra has 7 board of directors, including Alan Crane.

Name

Firm

Work History

Other Seats

Alan Crane

Alan joined Polaris Partners in 2002 and serves as an entrepreneur partner. In this role, he focuses on building and investing in healthcare companies. He has served as founder, chairman, and/or CEO in building eight Polaris companies. His current and past portfolio include: Momenta Pharmaceuticals, Visterra, Navitor Pharmaceuticals, Dyno Therapeutics, Pandion Therapeutics, KSQ Therapeutics, T2 Biosystems, Ocular Therapeutix, Sirtris Pharmaceuticals, Adnexus Therapeutics, Arsia Therapeutics, Seventh Sense Biosystems, Cerulean Pharma, and XTuit Pharmaceuticals. From 2002 to 2006, Alan was president and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA). He joined Momenta as the fifth employee and built it into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis and raising $275 million. The first product from Momenta’s pipeline achieved over $1B during its first year of sales. Prior to Polaris, Alan was senior vice president of global corporate development at Millennium Pharmaceuticals, where he was responsible for leading Millennium’s strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding and acquiring 19 development stage products. Among these products was Velcade®, which became the main basis of the company’s $9B acquisition by Takeda. Before joining Millennium, Alan was a marketing executive at DuPont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little. Alan received Ernst & Young’s Entrepreneur of the Year award for New England and is an Always-On Venture Capital 100 recipient. His current and former non-profit positions include: selection committee for the Harvard Life Lab, expert-in-residence at the Harvard School of Engineering, board member of the Boston Children’s Hospital Trust, founder and vice chair of the Autism Consortium, and president of the board of Gann Academy. Alan earned a BA in biology, summa cum laude, from Harvard College, an MA in cellular and developmental biology from Harvard Graduate School of Arts & Sciences, and an MBA, with honors, from Harvard Business School. He also spent two years studying towards an MD at Harvard Medical School. Close X Jack A. Khattar Board Director, President, CEO of Supernus Pharmaceuticals David M. Madden Board Director, Founder, Principal, Narrow River Management, LP Marian Nakada, PhD Board Director, VP of Venture Investments for Johnson & Johnson Innovation

Visterra

Brian Pereira

President & CEO, AMAG Pharmaceuticals; President & CEO, Tufts Medical Center Physician Organization; President & CEO, New England Health Care Foundation

Visterra

Carolyn Ng

Carolyn Ng, Ph.D., is Managing Director at Vertex Ventures HC. At Vertex Ventures HC, Carolyn is responsible for driving venture investments across biotechnology, medical devices, and health technology fields. Carolyn currently serves on the Board of Directors for Obsidian Therapeutics, Twentyeight-Seven Therapeutics, Bicycle Therapeutics (NASDAQ: BCYC), and Nuvaira. She was also a Board Observer for Visterra (acquired by Otsuka Pharmaceutical for $430 M) and Earlens. She has previously closely supported Vertex’s investment into Twelve (acquired by Medtronic for $458 M). Working across the U.S., Europe, and Asia, she plays an active role in expanding the geographical reach of Vertex HC and its portfolio companies for cross-border collaborations, business development, and syndication. She started her healthcare training in the oncology pharmacy department of the National University Cancer Institute of Singapore, where first-hand clinical experience inspired her to pursue scientific research in oncology. As an oncology scientist, she is deeply passionate about innovation that impacts patients’ lives. Prior to joining Vertex, Carolyn was a pharma strategy consultant at Deallus Consulting, a specialized London-headquartered life sciences consulting firm. Carolyn holds a Ph.D. in Cancer Molecular Biology from the National University of Singapore Graduate School for Integrative Sciences and Technology (NGS), where she was a recipient of the prestigious NGS Ph.D. Scholarship. She also holds a B.S. degree in Pharmacy with First Class Honors from the National University of Singapore, where she received the PSS Prize for Pharmaceutics awarded to the top graduating student in the class.

Visterra

Edwin Kania Jr.

Edwin M. Kania, Jr. is a co-founder of HDAI and serves on its Board. Mr. Kania is the co-founder of Flagship Pioneering, a leading life sciences venture firm. He was the firm’s Chairman between 2001 and 2014, and continues as Managing Partner for the Flagship funds raised during that period. Kania has 35 years of experience in the venture capital industry. Prior to co-founding Flagship in 2000, he served as Managing Partner at OneLiberty Ventures and as a General Partner at its predecessor firm, Morgan, Holland Ventures. Throughout his professional career, Kania has operated as an investor and active partner to entrepreneurs in company building. His direct investment experience covers over 100 companies. In addition, he has been intimately involved in the launch and development of nearly twenty companies as the founding, lead or co-lead investor, and on occasion has assumed operating roles in support of management. The total value of the companies in which Kania has participated as founding or lead investor exceeds $10 billion. Kania presently serves on the Board of several private companies and has been a Director for numerous publicly-traded and private companies. He has also been a long-time Director of MassBio, a not-for-profit organization representing the Massachusetts biopharmaceutical industry, and is a member of Harvard Partners’ Innovation Advisory Board. Kania earned his undergraduate degree in physics from Dartmouth College and his MBA from Harvard Business School.

Visterra

Kevin Bitterman

As a Partner at Atlas Venture, Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO), Kinaset Therapeutics and Curie Therapeutics. He is a co-founder and board member of Disc Medicine, and is chair of the board of Remix Therapeutics and Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic (NASDAQ: MORF) and Visterra (acquired by Otsuka). Kevin previously served as a director of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM) and Taris Biomedical (acquired by Johnson & Johnson) among other ventures. Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004.

Visterra

Name

Alan Crane

Brian Pereira

Carolyn Ng

Edwin Kania Jr.

Kevin Bitterman

Firm

Work History

Alan joined Polaris Partners in 2002 and serves as an entrepreneur partner. In this role, he focuses on building and investing in healthcare companies. He has served as founder, chairman, and/or CEO in building eight Polaris companies. His current and past portfolio include: Momenta Pharmaceuticals, Visterra, Navitor Pharmaceuticals, Dyno Therapeutics, Pandion Therapeutics, KSQ Therapeutics, T2 Biosystems, Ocular Therapeutix, Sirtris Pharmaceuticals, Adnexus Therapeutics, Arsia Therapeutics, Seventh Sense Biosystems, Cerulean Pharma, and XTuit Pharmaceuticals. From 2002 to 2006, Alan was president and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA). He joined Momenta as the fifth employee and built it into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis and raising $275 million. The first product from Momenta’s pipeline achieved over $1B during its first year of sales. Prior to Polaris, Alan was senior vice president of global corporate development at Millennium Pharmaceuticals, where he was responsible for leading Millennium’s strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding and acquiring 19 development stage products. Among these products was Velcade®, which became the main basis of the company’s $9B acquisition by Takeda. Before joining Millennium, Alan was a marketing executive at DuPont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little. Alan received Ernst & Young’s Entrepreneur of the Year award for New England and is an Always-On Venture Capital 100 recipient. His current and former non-profit positions include: selection committee for the Harvard Life Lab, expert-in-residence at the Harvard School of Engineering, board member of the Boston Children’s Hospital Trust, founder and vice chair of the Autism Consortium, and president of the board of Gann Academy. Alan earned a BA in biology, summa cum laude, from Harvard College, an MA in cellular and developmental biology from Harvard Graduate School of Arts & Sciences, and an MBA, with honors, from Harvard Business School. He also spent two years studying towards an MD at Harvard Medical School. Close X Jack A. Khattar Board Director, President, CEO of Supernus Pharmaceuticals David M. Madden Board Director, Founder, Principal, Narrow River Management, LP Marian Nakada, PhD Board Director, VP of Venture Investments for Johnson & Johnson Innovation

President & CEO, AMAG Pharmaceuticals; President & CEO, Tufts Medical Center Physician Organization; President & CEO, New England Health Care Foundation

Carolyn Ng, Ph.D., is Managing Director at Vertex Ventures HC. At Vertex Ventures HC, Carolyn is responsible for driving venture investments across biotechnology, medical devices, and health technology fields. Carolyn currently serves on the Board of Directors for Obsidian Therapeutics, Twentyeight-Seven Therapeutics, Bicycle Therapeutics (NASDAQ: BCYC), and Nuvaira. She was also a Board Observer for Visterra (acquired by Otsuka Pharmaceutical for $430 M) and Earlens. She has previously closely supported Vertex’s investment into Twelve (acquired by Medtronic for $458 M). Working across the U.S., Europe, and Asia, she plays an active role in expanding the geographical reach of Vertex HC and its portfolio companies for cross-border collaborations, business development, and syndication. She started her healthcare training in the oncology pharmacy department of the National University Cancer Institute of Singapore, where first-hand clinical experience inspired her to pursue scientific research in oncology. As an oncology scientist, she is deeply passionate about innovation that impacts patients’ lives. Prior to joining Vertex, Carolyn was a pharma strategy consultant at Deallus Consulting, a specialized London-headquartered life sciences consulting firm. Carolyn holds a Ph.D. in Cancer Molecular Biology from the National University of Singapore Graduate School for Integrative Sciences and Technology (NGS), where she was a recipient of the prestigious NGS Ph.D. Scholarship. She also holds a B.S. degree in Pharmacy with First Class Honors from the National University of Singapore, where she received the PSS Prize for Pharmaceutics awarded to the top graduating student in the class.

Edwin M. Kania, Jr. is a co-founder of HDAI and serves on its Board. Mr. Kania is the co-founder of Flagship Pioneering, a leading life sciences venture firm. He was the firm’s Chairman between 2001 and 2014, and continues as Managing Partner for the Flagship funds raised during that period. Kania has 35 years of experience in the venture capital industry. Prior to co-founding Flagship in 2000, he served as Managing Partner at OneLiberty Ventures and as a General Partner at its predecessor firm, Morgan, Holland Ventures. Throughout his professional career, Kania has operated as an investor and active partner to entrepreneurs in company building. His direct investment experience covers over 100 companies. In addition, he has been intimately involved in the launch and development of nearly twenty companies as the founding, lead or co-lead investor, and on occasion has assumed operating roles in support of management. The total value of the companies in which Kania has participated as founding or lead investor exceeds $10 billion. Kania presently serves on the Board of several private companies and has been a Director for numerous publicly-traded and private companies. He has also been a long-time Director of MassBio, a not-for-profit organization representing the Massachusetts biopharmaceutical industry, and is a member of Harvard Partners’ Innovation Advisory Board. Kania earned his undergraduate degree in physics from Dartmouth College and his MBA from Harvard Business School.

As a Partner at Atlas Venture, Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO), Kinaset Therapeutics and Curie Therapeutics. He is a co-founder and board member of Disc Medicine, and is chair of the board of Remix Therapeutics and Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic (NASDAQ: MORF) and Visterra (acquired by Otsuka). Kevin previously served as a director of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM) and Taris Biomedical (acquired by Johnson & Johnson) among other ventures. Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004.

Other Seats

Visterra

Visterra

Visterra

Visterra

Visterra

Visterra Management Team

7 Team Members

Visterra has 7 executives. Visterra's current Chief Executive Officer, President is Brian J.G. Pereira.

Name

Work History

Title

Status

Brian J.G. Pereira

Chief Executive Officer, President

Current

David A Arkowitz

Chief Financial Officer

Current

Zachary H Shriver

Chief Security Officer

Current

Jorg Thommes

Senior Vice President

Current

Steven B Brugger

Chief Executive Officer

Former

Name

Brian J.G. Pereira

David A Arkowitz

Zachary H Shriver

Jorg Thommes

Steven B Brugger

Work History

Title

Chief Executive Officer, President

Chief Financial Officer

Chief Security Officer

Senior Vice President

Chief Executive Officer

Status

Current

Current

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.